Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Equity Average (2022 - 2025)

Historic Equity Average for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$98.3 million.

  • BioXcel Therapeutics' Equity Average fell 2291.7% to -$98.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.3 million, marking a year-over-year decrease of 2291.7%. This contributed to the annual value of -$74.8 million for FY2024, which is 83819.02% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Equity Average stood at -$98.3 million for Q3 2025, which was down 2291.7% from -$98.9 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Equity Average peaked at $179.1 million during Q2 2022, and registered a low of -$98.9 million during Q2 2025.
  • Moreover, its 4-year median value for Equity Average was -$56.5 million (2023), whereas its average is -$10.1 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 36032.12% in 2024, then crashed by 2291.7% in 2025.
  • Over the past 4 years, BioXcel Therapeutics' Equity Average (Quarter) stood at $101.9 million in 2022, then tumbled by 147.66% to -$48.6 million in 2023, then crashed by 84.04% to -$89.4 million in 2024, then decreased by 9.99% to -$98.3 million in 2025.
  • Its last three reported values are -$98.3 million in Q3 2025, -$98.9 million for Q2 2025, and -$91.6 million during Q1 2025.